Internal Medicine Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Pathology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
Sci Rep. 2020 Jun 30;10(1):10651. doi: 10.1038/s41598-020-67615-0.
Papillary thyroid carcinoma (PTC) is considered the most prevalent thyroid malignancy. The association between Hashimoto's thyroiditis (HT) and PTC is still unclear. We aimed to examine the clinicopathological impact of immunohistochemical staining of FOXP3 and Cytokeratin 19 in PTC and concomitant HT and their correlation with patients' outcome and survival. Eighty thyroid biopsies obtained from patients with PTC were immunostained by FOXP3 and CK19.The patients were treated by radioactive iodine (I) and followed up. FOXP3 and CK19 expression were detected in 45% and 80% studied cases of PTC respectively. 16.7% of PTC with associated HT showed FOXP3+ lymphocytes in lymphocytic infiltrate of HT, while most of PTC associated HT express cytoplasmic CK19 positive Hurtle cells. FOXP3 was more expressed in PTC female patients more than 45 years with higher stage, lymph node, and distant metastasis, extracapsular extension, number of Idoses, and cumulative radioiodine doses with a highly statistically significant difference (p < 0.001). The relation was significant between CK19 immunostaining as regard 10-year Overall Survival and death (p value = 0.027 and 0.036, respectively). HT represents a step in the process of autoimmune inflammatory disease ending by the evolution of PTC with better prognosis, therefore appropriate follow up of these cases is needed. FOXP3 tends to be more expressed in PTC cases with worse prognostic variables and is predictable to become a recent prognostic and targeted therapy for PTC. There was a significant relation between CK19 immunostaining and 10 year overall survival.
甲状腺乳头状癌 (PTC) 被认为是最常见的甲状腺恶性肿瘤。桥本甲状腺炎 (HT) 与 PTC 之间的关系尚不清楚。我们旨在研究 FOXP3 和细胞角蛋白 19 在 PTC 及其合并 HT 中的免疫组织化学染色的临床病理影响及其与患者预后和生存的相关性。对 80 例 PTC 患者的甲状腺活检进行了 FOXP3 和 CK19 免疫染色。患者接受放射性碘 (I) 治疗并进行随访。在研究的 PTC 病例中，FOXP3 和 CK19 的表达分别为 45%和 80%。在伴有 HT 的 PTC 中，16.7%的病例在 HT 的淋巴细胞浸润中显示 FOXP3+淋巴细胞，而大多数伴有 HT 的 PTC 表达细胞质 CK19 阳性的 Hurthle 细胞。FOXP3 在 45 岁以上的女性 PTC 患者中表达更高，且分期更高、淋巴结和远处转移、包膜外扩展、Idoses 数量和累积放射性碘剂量更高，差异具有统计学意义（p<0.001）。CK19 免疫染色与 10 年总生存率和死亡率之间存在显著关系（p 值分别为 0.027 和 0.036）。HT 代表自身免疫性炎症性疾病过程中的一个阶段，最终发展为预后较好的 PTC，因此需要对这些病例进行适当的随访。FOXP3 在预后较差的 PTC 病例中表达更高，且可能成为 PTC 的新的预后和靶向治疗标志物。CK19 免疫染色与 10 年总生存率之间存在显著关系。
